Development Status

​More than 900 subjects have been treated with naronapride in clinical trials, including three Phase-2 trials, where naronapride showed efficacy in both lower and upper GI indications.​A Thorough QT (TQT) study testing the cardiac safety of naronapride has also been completed. The results confirmed the cardiac safety profile of naronapride at both therapeutic and supra-therapeutic doses.